TISIDB

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Golgi apparatus, Golgi stack membrane Single-pass type II membrane protein
Domain	PF16363 GDP-mannose 4 PF11803 UDP-glucuronate decarboxylase N-terminal
Function	Catalyzes the NAD-dependent decarboxylation of UDP-glucuronic acid to UDP-xylose. Necessary for the biosynthesis of the core tetrasaccharide in glycosaminoglycan biosynthesis.

> Gene Ontology [ TOP ]
Biological Process	GO:0009225 nucleotide-sugar metabolic process GO:0009226 nucleotide-sugar biosynthetic process GO:0033319 UDP-D-xylose metabolic process GO:0033320 UDP-D-xylose biosynthetic process GO:0051259 protein oligomerization GO:0051262 protein tetramerization
Molecular Function	GO:0016829 lyase activity GO:0016830 carbon-carbon lyase activity GO:0016831 carboxy-lyase activity GO:0048037 cofactor binding GO:0048040 UDP-glucuronate decarboxylase activity GO:0050662 coenzyme binding GO:0051287 NAD binding GO:0070403 NAD+ binding
Cellular Component	GO:0005795 Golgi stack GO:0031984 organelle subcompartment GO:0031985 Golgi cisterna GO:0032580 Golgi cisterna membrane GO:0098791 Golgi subcompartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00520 Amino sugar and nucleotide sugar metabolism hsa01100 Metabolic pathways
Reactome	-

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between UXS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of UXS1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.54	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of UXS1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.243	0.37
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.28	0.892
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.221	0.89
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.097	0.714
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.368	0.845
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.246	0.916
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.032	0.936
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.277	0.859
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.209	0.906
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.172	0.915
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.82	0.726
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.098	0.219

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of UXS1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UXS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UXS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UXS1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UXS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of UXS1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between UXS1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	UXS1
Name	UDP-glucuronate decarboxylase 1
Aliases	FLJ23591; SDR6E1; short chain dehydrogenase/reductase family 6E, member 12; UXS-1; UDP-glucuronic acid decar ......
Chromosomal Location	2q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting UXS1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse UXS1